KRAS mutations have recently been described as an independent adverse prognostic factor in pediatric KMT2Ar AML by the Japanese Pediatric Leukemia/Lymphoma Study Group, which was validated using a smaller cohort of adult KMT2Ar patients [36]. This evidence concerns the gene KRAS and lymphoma.